Targeted therapy in older adults with Alzheimer disease: a review
- 18 June 2025
- journal article
- review article
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 31 (5) , 493-500
Abstract
One of the most pressing issues today is the somatic and mental health of older adults due to increasing life expectancy and expanding diagnostic capabilities for various diseases. Alzheimer disease has a significant impact on the quality of life of patients and their families and results in substantial economic and social consequences for society. Patients with Alzheimer disease require continuous care and support, which demands considerable resources from health care and social service systems. Moreover, Alzheimer disease leads to reduced work productivity and increased health care expenditures. This review analyzes foreign and Russian articles published in the past 5 years in Scopus, PubMed Central, the Cochrane Library, and BMJ Case Reports regarding targeted therapy for Alzheimer disease, one of the most common neurodegenerative disorders that reduce quality of life. This review considers the main principles of targeted therapy used in older adults with Alzheimer disease are considered, along with its advantages, limitations, and future perspectives for this therapeutic approach.Keywords
This publication has 35 references indexed in Scilit:
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Alzheimer's disease drug development pipeline: 2024Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugsBiochemical Pharmacology, 2023
- Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy VolunteersClinical Pharmacology & Therapeutics, 2021
- PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer’s disease-causing Presenilin-1 E280A mutation carriersNeuroImage: Clinical, 2021
- Alzheimer's disease drug development pipeline: 2021Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2021
- Dementia prevention, intervention, and care: 2020 report of the Lancet CommissionThe Lancet, 2020
- Advances and considerations in AD tau-targeted immunotherapyNeurobiology of Disease, 2020
- Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumabAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018